AviadoBio Presents New Safety and Biomarker Data from the Phase 1/2 ASPIRE-FTD Trial at the International Conference on Frontotemporal Dementias Business Wire Evolving biomarker data show early signs of dose-dependent increase in cerebrospinal fluid (CSF) progranulinSerum neurofilament light chain (NfL) at/below baseline in all patients with 52-week dataAVB-101 continues to be well tolerated, with no serious adverse events related to treatment to date and no immunosuppression required
Lattice Collaborates with Arm to Advance Secure, Adaptable AI Data Center Infrastructure Business Wire Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today announced a collaboration with Arm to enable secure control, management, and platform adaptability for AI infrastructure. Combining Arm® AGI CPU server platforms with Lattice FPGAs and AMI firmware creates a solution that provides advanced security, manageability, connectivity, and flexibility for next-generation AI [...]
KBRA Releases Opal Group European CLO Summit Recap Business Wire KBRA releases its recap of Opal Group’s European CLO Summit, held at the London Marriott Hotel Grosvenor Square on 6 October 2026. The conference brought together collateralised loan obligation (CLO) market participants who discussed the strong European issuance and investor demand, alongside tighter transaction economics, limited primary loan supply, and increasing credit dispersion. Panellists generally [...]
AeraHUB 26 NYC Brings the Decision-Centric Enterprise to Life October 7, 2026 Global leaders share how they are applying decision intelligence to the decisions that run the business
KBRA Releases Research – Opal Group European Private Credit & ABF Summit Recap October 6, 2026 KBRA releases its recap of Opal Group’s European Private Credit & ABF Summit, held at the London Marriott Hotel Grosvenor Square on 5 October 2026. The conference brought together market participants to discuss the performance and outlook for European private credit, the continued expansion of asset-based finance (ABF), and the growing use of fund finance, [...]
AEM Expands Elements Platform to Deliver Full-Spectrum Environmental Resilience October 5, 2026 Elements 360, Elements Weather, and Elements Protect give organizations purpose-built applications for every environmental risk decision, helping them plan earlier, respond faster, and protect people, infrastructure, and operations when conditions threaten.
EADV 2026: Long-Term Disease Control for up to Five Years in Patients With Moderate-to-Severe Atopic Dermatitis Treated With Lebrikizumab October 1, 2026 Late-breaking results from the Phase 3b ADlong clinical study presented by Almirall at EADV 2026 show treatment outcomes over time with up to five years of lebrikizumab treatment in moderate-to-severe atopic dermatitis: sustained efficacy and safety demonstrated by 92.9% of patients achieving EASI-75 and 73.8% achieving EASI-90 at the end of the study (week 108)1. At week 108 of continuous treatment, 66.7% of patients achieved clear or almost-clear skin, while 78.0% reported an absolute pruritus score of four or less on the Pruritus Numerical Rating Scale1, indicating low levels of itch, one of the most bothersome symptoms for patients. The ADlong study reflects the ongoing commitment to generating long-term evidence for lebrikizumab and the opportunity to achieve long-term disease control in AD treatment. Almirall’s scientific presence at EADV 2026 includes more than 20 abstracts across atopic dermatitis, psoriasis and actinic keratosis, alongside three expert-led events: two symposia and an interactive AD Morning Hub.
KBRA Releases DealCatalyst UK Mortgage Finance Conference Recap September 30, 2026 KBRA releases its recap of the DealCatalyst UK Mortgage Finance Conference held at The Landmark Hotel in London on 28 September. The report highlights key themes across housing affordability, refinancing, buy-to-let (BTL), specialist lending, and funding and liquidity management. Panellists described mortgage performance as resilient despite elevated borrowing costs and persistent housing supply constraints. Discussions [...]
Almirall Advances Skin Science and Shares New Evidence Across Its Dermatology Portfolio at EADV 2026 September 30, 2026 Almirall’s scientific programme at EADV 2026 showcases advances in critical skin diseases, including atopic dermatitis, psoriasis and actinic keratosis, through more than 20 abstracts, including a late-breaking abstracts, alongside two expert-led symposia and an interactive industry AD hub session. New clinical data show consistent efficacy and effectiveness in atopic dermatitis treatment across body regions with lebrikizumab, including high-impact areas such as the face and neck1,2, while late-breaking ADlong results highlight sustained improvements in skin signs and itch with up to five years of treatment3. Final two-year data from the POSITIVE clinical study demonstrate the benefits on patient overall well-being and quality of life during tildrakizumab treatment4,5, and further data show evidence in patients with high disease burden and previous biologic treatment6,7. Almirall’s commitment to medical dermatology is reflected by its Gold Sponsorship of EADV 2026 and the launch of the ‘Face It’-campaign to raise awareness of the burden of atopic dermatitis with face and neck involvement, addressing the broader impact of skin diseases on patients.
Lattice to Showcase AI-Driven Low Power FPGA Innovation at FPGA Horizons Conference September 29, 2026 Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today announced its participation in the upcoming FPGA Horizons conference, taking place on October 6 – 7, 2026 in London. As part of the conference’s technical program, Lattice will deliver a Tech Talk presentation and a hands-on workshop, and host a demo showcase [...]